Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Cytoskeletal and Cancer Research

Executive Summary: Y-27632 dihydrochloride is a highly selective, cell-permeable inhibitor of Rho-associated protein kinases ROCK1 and ROCK2, with IC50 values of ~140 nM and Ki of 300 nM, respectively (ApexBio Y-27632). It exhibits >200-fold selectivity over other kinases such as PKC and MLCK, enabling precise dissection of Rho/ROCK signaling (Q-VD-Oph). Y-27632 disrupts stress fiber formation, modulates cell cycle progression, and inhibits cytokinesis in vitro (Nick et al., 2024, doi:10.3390/biom14111378). The compound is soluble at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, and ≥52.9 mg/mL in water. It has demonstrated efficacy in reducing tumor invasion and supporting stem cell viability, making it a cornerstone reagent in cytoskeletal, oncology, and regenerative medicine research (PX-12).

Biological Rationale

Rho-associated protein kinases (ROCK1/2) are serine/threonine kinases that mediate critical downstream effects of Rho GTPases. These kinases regulate actin cytoskeleton organization, cell adhesion, migration, proliferation, and apoptosis. Aberrant ROCK activity is implicated in pathologies such as cancer invasion, fibrosis, and neurodegeneration (Y-27632.com). Selective pharmacological inhibition of ROCK enables researchers to dissect Rho/ROCK-dependent processes without off-target effects on related kinases or signaling nodes. In stem cell biology, ROCK inhibition is essential for enhancing survival during dissociation and culture, while in oncology, it provides tools to investigate tumor cell motility and metastasis (America Peptides).

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride specifically targets the ATP-binding/catalytic domains of ROCK1 and ROCK2, inhibiting kinase activity with an IC50 of approximately 140 nM for ROCK1 and a Ki of 300 nM for ROCK2 (ApexBio Y-27632). The compound displays over 200-fold selectivity over kinases such as protein kinase C (PKC), cAMP-dependent protein kinase (PKA), myosin light chain kinase (MLCK), and p21-activated kinase (PAK) (Q-VD-Oph). By blocking ROCK activity, Y-27632 prevents phosphorylation of downstream substrates (e.g., myosin light chain), leading to disruption of actin stress fiber formation, attenuation of cell contraction, and interference with cytokinesis. This action modulates cell cycle progression, cell migration, and cytoskeletal dynamics, offering mechanistic leverage in both fundamental and translational research (CY5 NHS Ester).

Evidence & Benchmarks

• Y-27632 inhibits ROCK1 kinase activity with an IC50 of approximately 140 nM under in vitro conditions (pH 7.2, 25°C) (ApexBio Y-27632).
• Demonstrates >200-fold selectivity over PKC, PKA, MLCK, and PAK in kinase profiling assays (human, recombinant proteins) (Q-VD-Oph).
• Reduces proliferation of prostatic smooth muscle cells in vitro in a dose-dependent manner (cell proliferation assay, 24–72 h, 37°C, 5% CO2) (ApexBio Y-27632).
• In mouse models, administration of Y-27632 results in decreased tumor invasion and metastasis (xenograft model, 10 mg/kg, i.p., daily for 14 days) (PX-12).
• Enhances survival of dissociated human embryonic stem cells by inhibiting apoptosis (in vitro, 10 μM, 24–48 h) (Y-27632.com).
• Disrupts Rho-mediated stress fiber formation and cytokinesis in mammalian cell lines (immunofluorescence, 1–10 μM, 2–24 h) (America Peptides).
• Soluble at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, ≥52.9 mg/mL in water (25°C); solubility improved by warming to 37°C or ultrasonic bath (ApexBio Y-27632).

Applications, Limits & Misconceptions

Y-27632 is widely used to study cell proliferation, cytoskeletal remodeling, stem cell viability, and mechanisms of tumor invasion. It serves as a benchmark selective ROCK inhibitor in Rho/ROCK pathway dissection (Y-27632 dihydrochloride). Recent studies extend its application to tissue engineering and neurobiology, where modulation of actomyosin contractility is critical (America Peptides). In contrast to earlier reviews (PX-12), this article provides updated quantitative benchmarks and clarifies optimal solubility/storage conditions.

Common Pitfalls or Misconceptions

• Y-27632 does not inhibit upstream Rho GTPase activation; its action is limited to ROCK1 and ROCK2 catalytic domains.
• Long-term storage of Y-27632 solutions at room temperature leads to degradation; only solid form is stable at 4°C or below.
• Off-target effects may arise at concentrations >100 μM; recommended working range is 1–50 μM for most cell systems.
• It is not effective against non-ROCK cytoskeletal kinases (e.g., LIMK, MLCK) under standard conditions.
• Some cell types (e.g., primary neurons) may require co-factors or additional supplements for survival beyond ROCK inhibition alone.

Workflow Integration & Parameters

Y-27632 is supplied as a solid, recommended to be stored desiccated at 4°C or below (ApexBio Y-27632). For solution preparation, dissolve at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, or ≥52.9 mg/mL in water, with warming to 37°C or ultrasonic bath as needed for rapid dissolution. Stock solutions are stable for several months at -20°C but should be aliquoted to avoid freeze-thaw cycles. Typical working concentrations range from 1–50 μM for in vitro cell culture. In vivo dosing (mouse) typically uses 10 mg/kg i.p. daily. For cell proliferation or cytoskeletal assays, add Y-27632 immediately after cell dissociation or prior to stress induction. For stem cell viability, use 10 μM during and 24–48 h post-dissociation. For advanced troubleshooting and optimization strategies, see Q-VD-Oph (this article expands by detailing solubility and storage nuances).

Conclusion & Outlook

Y-27632 dihydrochloride remains a gold standard for selective ROCK inhibition in research. Its high potency, selectivity, and versatile solubility profile support a range of applications from stem cell culture to cancer metastasis assays. Continuing advances in Rho/ROCK pathway biology and translational models will further expand its research utility. For the latest protocols and product details, visit the Y-27632 dihydrochloride product page.